GENB (Generate Biomedicines) Notes Receivable: $0.00 Mil (As of Dec. 2025)


GENB Generate Biomedicines Inc GENB
6 GF Score
Price $16.92
! 2 Warning Signs
View Full Analysis

What is Generate Biomedicines Notes Receivable?

Generate Biomedicines GENB +2.18% 6 Notes Receivable is $0.00 Mil as of Dec. 2025. GuruFocus rates GENB with a GF Score™ of 6/100. The stock has 2 warning signs investors should review.

Generate Biomedicines's Notes Receivable for the quarter that ended in Dec. 2025 was $0.00 Mil.

Generate Biomedicines Notes Receivable Related Terms

Generate Biomedicines Notes Receivable Historical Data

* Premium members only.

The historical data trend for Generate Biomedicines's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Generate Biomedicines Notes Receivable Chart

Generate Biomedicines Annual Data
Trend Dec24 Dec25
Notes Receivable
0.00 0.00

Generate Biomedicines Semi-Annual Data
Dec24 Dec25
Notes Receivable 0.00 0.00
GENB
6GF Score
Generate Biomedicines Inc GENB
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Generate Biomedicines Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of $0.00 Mil mean?
Generate Biomedicines (GENB) has a Notes Receivable of $0.00 Mil as of Dec. 2025. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Generate Biomedicines and its competitors.
Is Generate Biomedicines' Notes Receivable too high?
Generate Biomedicines' current Notes Receivable is $0.00 Mil. Overall, Generate Biomedicines has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Generate Biomedicines' Notes Receivable compare to PVLA and SLBT?
Generate Biomedicines' Notes Receivable of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Generate Biomedicines and its competitors. Generate Biomedicines's current Notes Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Generate Biomedicines stock overvalued right now?
Generate Biomedicines (GENB) has a current Notes Receivable of $0.00 Mil. The current Notes Receivable is $0.00 Mil. Generate Biomedicines' overall GF Score™ is 6/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Generate Biomedicines (GENB), the current Notes Receivable is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Generate Biomedicines Business Description

Address 101 South Street, Suite 900, Somerville, MA, USA, 02143
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.
6GF Score

Get the complete analysis for GENB

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.92
Price